• Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Repligen Corp

+ Add to Watchlist

RGEN:US

22.4100 USD 0.1900 0.86%

As of 20:10:00 ET on 07/30/2014.

Snapshot for Repligen Corp (RGEN)

Open: 22.5500 Day's Range: 22.1900 - 23.0900 Volume: 222,433
Previous Close: 22.2200 52wk Range: 9.4100 - 24.6800 1-Yr Rtn: +120.35%

Stock Chart for RGEN

No chart data available.
  • RGEN:US 22.4100
  • 1D
  • 1M
  • 1Y
22.2200
Interactive RGEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for RGEN

Current P/E Ratio (ttm) 37.7351
Estimated P/E(12/2014) 83.0000
Relative P/E vs. SPX 2.0992
Earnings Per Share (USD) (ttm) 0.5939
Est. EPS (USD) (12/2014) 0.2700
Est. PEG Ratio -
Market Cap (M USD) 718.01
Shares Outstanding (M) 32.04
30 Day Average Volume 444,383
Price/Book (mrq) 6.5964
Price/Sale (ttm) 10.4873
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/11/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for RGEN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for RGEN

Repligen Corporation is a biotechnology company. The Company develops therapeutics for the treatment of diseases of the central nervous system. Repligen owns owns intellectual property on monoclonal antibody and antibody fusion products.

Walter C HerlihyPresident/CEO/TreasurerJon K SnodgresChief Financial Officer
Tony J HuntChief Operating OfficerDaniel P WittSenior VP:Global Operations
More Company Profile & Key Executives for RGEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil